META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON FINERENONE FOR CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE
META-ANALISIS UJI ACAK TERKONTROL FINERENON TERHADAP LUARAN KARDIOVASKULAR PADA DIABETES TIPE 2 DAN PENYAKIT GINJAL KRONIK
Abstract
Patients with chronic kidney disease and type 2 diabetes mellitus are at high risk for cardiovascular events. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, shows potential as an additional therapy with cardioprotective effects. We conducted a meta-analysis based on data from randomized controlled trials by systematically searching the PubMed and ScienceDirect databases, using the PICOS framework: chronic kidney disease and type 2 diabetes mellitus (P); finerenone (I); placebo (C); cardiovascular outcomes (O); and randomized controlled trials (S). We included articles published within the last 10 years and available in full-text format. A total of 4 RCTs were included in this analysis. Statistical analysis was performed using the Random Effect Model. The analysis showed that finerenone reduced the odds of non-fatal myocardial infarction by 9% compared to placebo (OR 0.91; 95% CI: 0.80–1.03) and reduced the risk of hospitalization due to heart failure by 17% (OR 0.73; 95% CI: 0.66–0.82). All statistical results were significant, except for non-fatal myocardial infarction. The heterogeneity level was assessed as low to moderate (I² = 10%, 0%, and 58%). Risk of bias assessment using the RoB-2 tool indicated that all included studies had a low risk of bias. Finerenone demonstrated better outcomes compared to placebo, suggesting its potential benefit in improving cardiovascular outcomes in this population.
References
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003
Khan AB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107-111. doi:10.2991/jegh.k.191028.001
Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012. BMJ Open Diabetes Res Care. 2016;4(1). doi:10.1136/bmjdrc 2015 000154.
Fenta ET, Eshetu HB, Kebede N, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):1-12. doi:10.1186/s13098-023-01202-x
Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: A review of the evidence. Diabetes, Metab Syndr Obes. 2020;13(1):161-174. doi:10.2147/DMSO.S233538
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116
Neuen BL, Vaduganathan M, Claggett BL, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(5):450–462. doi:10.1161/CIRCULATIONAHA.123.067584
Xie Y, Wu H, Li X, et al. Comparison of effects of finerenone relative to SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes: a network meta-analysis. Cardiovasc Diabetol. 2022;21:101. doi:10.1186/s12933-022-01676-5
Frampton JE. Finerenone: First Approval. Drugs. 2021;81(15):1787-1794. doi:10.1007/s40265-021-01599-7
Alhomoud IS, Albekery MA, Alqadi R, et al. Finerenone in diabetic kidney disease: a new frontier for slowing disease progression. Front Med. 2025;12(6):1-11. doi:10.3389/fmed.2025.1580645
Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med. 2024;11(9):1-14. doi:10.3389/fcvm.2024.1476029
Rivera-Martinez JC, Sabina M, Khanani A, et al. Effect of finerenone in cardiovascular and renal outcomes: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2025;39(1):185–196. doi:10.1007/s10557-024-07666-x
Marzolla V, Infante M, Armani A, Rizzo M, Caprio M. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Expert Opin Drug Saf. 2022;21(9):1161-1170. doi:10.1080/14740338.2022.2130889
Swamy S, Noor SM, Mathew RO. Cardiovascular Disease in Diabetes and Chronic Kidney Disease. J Clin Med. 2023;12(22):6984. doi:10.3390/jcm12226984
Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of new-onset heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437–447. doi:10.1161/CIRCULATIONAHA.121.057983
Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30:3758–3764. doi:10.1038/s41591-024-03264-4
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Hear J. 2022;43(62219-29). doi:10.1093/eurheartj/ehab777
Sarafidis P, Agarwal R, Pitt B, et al. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023;18(5):602-612. doi:10.2215/CJN.0000000000000149
Agarwal R, Humle K, Klanger B, et al. Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease—The FIDELITY Pooled Analysis. Eur Heart J. 2024;15(9):1861-1864. doi:10.1007/s13300-024-01591-w
Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;43(6):474-484. doi:10.1056/NEJMoa2025845
Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone: a selective mineralocorticoid receptor antagonist with anti-inflammatory and anti-fibrotic effects. Mol Cell Endocrinol. 2014;382(1):124–135. doi:10.1016/j.mce.2013.08.019
Usman MS, Khan MS, Butler J. The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease. ADA Clin Compend. 2021;1(1):13-18. doi:10.2337/db20211-13
Agarwal R, Filippatos G, Pitt B, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Hear J. 2022;43(20):1989. doi:10.1093/eurheartj/ehab886
Rossing P, Anker SD, Filippatos G, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022;45(12):2991-2998. doi:10.2337/dc22-0294
González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-513. doi:10.1080/07853890.2023.2171110
Arici M, Altun B, Araz M, et al. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med. 2024;11(June):1-19. doi:10.3389/fmed.2024.1384454
Lerma E V., Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022;15(5):501-513. doi:10.1080/17512433.2022.2094770
Seidu S, Almaqhawi A, Abdool M, Kunutsor SK, Davies MJ, Khunti K. Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obes Metab. 2022;24(8):1469-1482. doi:10.1111/dom.14715
Docherty KF, Henderson AD, Jhund PS, et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2025;151(1):45-58. doi:10.1161/CIRCULATIONAHA.124.072011
Copyright (c) 2026 Khairuman Fitrah Ananda, Abigail Christine Sarumpaet, Agustina Sianturi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
